LONDON, July 23 (Reuters) - The European Union's drug watchdog cast further doubt on recent studies suggesting a possible cancer risk with Sanofi-Aventis's widely-used Lantus diabetes drug. The ...

Civica plans to distribute its insulin glargine to pharmacies across the United States for $45 for a box of five pens. “Through the partnership we formed with Civica more than six years ago, BCBSA and ...

U.S. regulators took action Wednesday that will make it easier to get a cheaper, near-copy of a brand-name insulin at the drugstore. Doctors now have to specifically prescribe what’s called a ...

Merck on Thursday earned tentative Food and Drug Administration approval for its biosimilar version of Sanofi’s diabetes drug Lantus. Here are three things to know. Merck’s biosimilar, Lusdana Nexvue, ...

Lantus, a long-acting insulin glargine, offers stable 24-hour blood sugar control for people with type 1 and type 2 diabetes. It is often introduced when other treatments are insufficient, and can be ...